Feb 26, 2021 · Learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat. Black people are far more likely to live with cardiovascular diseases than other populations in …

Learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.

Dec 12, 2024 · Johnson & Johnson MedTech, the global leader in heart recovery, announced today that the U.S. Food and Drug Administration (FDA) has expanded the indications for the Impella 5.5 with SmartAssist and Impella CP with SmartAssist heart pumps, granting premarket approval (PMA) for use in specific pediatric patients with symptomatic acute ...

Nov 1, 2022 · Johnson & Johnson said on Tuesday it would buy heart pump maker Abiomed in a $16.6 billion deal, its biggest in nearly six years. J&J's offer of upfront payment of $380 per share represents a...

We relentlessly pursue mature innovation, both inside and beyond our own walls, that holds the highest potential for preventing, reversing, treating, and even curing the most prevalent forms of heart disease.

NEW BRUNSWICK, NJ (April 4, 2024) – Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia.

A Johnson & Johnson operating company released one of the world’s first FDA-approved coronary stents, the PALMAZ-SCHATZ Balloon-Expandable Stent. The tube-shaped coronary device that was inserted into arteries, revolutionized the field of cardiology, providing doctors with a new, lifesaving tool.

2 days ago · Johnson & Johnson is recruiting for an Associate /Area Clinical Consultant within the J&J Medtech - Heart Recovery division located in Boston South, MA & Rhode Island region. About Cardiovascular Fueled by innovation at the intersection of biology and technology, we’re developing the next generation of smarter, less invasive, more ...

Oct 9, 2024 · The acquisition of V-Wave extends Johnson & Johnson MedTech’s position in cardiovascular disease and provides an even greater opportunity to tackle heart failure, one of the most pressing unmet medical needs in healthcare today.

DANVERS, Mass., Aug. 12, 2024 – Abiomed, Inc., part of Johnson & Johnson MedTech 1, is celebrating 25 years of heart recovery by bringing together 25 patients to honor and celebrate their personal stories of heart recovery.